Skip to main content

IntregraGen Wins $2.5M Investment From DSM, Signs Molecular Dx Pact

NEW YORK (GenomeWeb News) — IntegraGen today said it has received a €2 million ($2.5 million) equity investment from DSM Venturing, with which it has also signed a research partnership to develop molecular diagnostics.
 
Under the terms of the agreement, IntegraGen will receive upfront fees, licensing fees, and funding to develop gene-based diagnostic and prognostic tests.
 
DSM, a branch of Royal DSM, will pay royalties earned from product commercialization, although each company will hold rights to developments falling within its area of focus.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.